EFB Dengue Literature Review

CD138

5 min read

CD138

Overview

CD138 (Syndecan-1) is a heparan sulphate proteoglycan expressed on epithelial cells and re-expressed upon terminal B cell differentiation into plasma cells. In B cell biology, CD138 is a canonical plasma cell marker: it is absent on circulating B cells and plasmablasts at early differentiation stages, then progressively upregulated as plasmablasts mature toward long-lived plasma cells. In peripheral blood flow cytometry, CD138 expression discriminates two maturation stages within the circulating antibody-secreting cell (ASC) population:

  • CD138⁻ ASCs — early-stage plasmablasts, actively proliferating
  • CD138⁺ ASCs — more mature, still-circulating plasmablasts with greater CD138 expression

Both subsets are Ki67⁺ in active disease (proliferative), and both are phenotypically IgD⁻CD27^hiCD38^hi by conventional B cell gating.

Key Points from Literature

  • Both CD138⁻ and CD138⁺ circulating ASCs in SLE are Ki67⁺: During SLE flares, all circulating ASCs — including the CD138⁻ early-stage subset — are Ki67⁺, establishing that peripheral blood ASCs in active disease are proliferative plasmablasts in various stages of maturation, not resting plasma cells. CD138⁺ ASCs in bone marrow from non-flaring patients were Ki67⁻, confirming the quiescent long-lived plasma cell phenotype in the marrow compartment (see Tipton2015 - ASC Diversity and Origin in SLE, polychromatic flow cytometry).
  • CD138⁻ and CD138⁺ ASCs are clonally connected: NGS analysis of simultaneously sorted CD138⁻ and CD138⁺ ASC fractions demonstrated shared clonal lineages, with sequences in both populations tracing back to common precursors including acN cells and naive B cells. The two populations represent a maturation continuum, not distinct cell types (see Tipton2015 - ASC Diversity and Origin in SLE).
  • CD138⁻ ASCs are more abundant and more polyclonal: D20 values averaged ~199 for CD138⁻ ASCs vs. ~127 for CD138⁺ ASCs in SLE patients (vs. ~21 and ~11 post-vaccination), suggesting that the CD138⁺ fraction contains a slightly enriched proportion of expanded clones, consistent with clonal selection as plasmablasts mature (see Tipton2015 - ASC Diversity and Origin in SLE).
  • ASC gating in Tipton2015: The combined gate CD19⁺IgD⁻CD27^hiCD38^hi identifies the full ASC population; subsequent CD138 staining subdivides into CD138⁻ (early) and CD138⁺ (mature) fractions. This gate was used to confirm that SLE flares contain 15–52% of IgD⁻CD19⁺ B cells as ASCs vs. ~2% in healthy subjects (see Tipton2015 - ASC Diversity and Origin in SLE).
  • SHM differences between CD138⁻ and CD138⁺ subsets: Both subsets showed lower average VH mutation rates in SLE (4.98%) compared with vaccination responses (7.33%), but the pattern was similar between CD138⁻ and CD138⁺ fractions — arguing against the idea that CD138⁺ cells represent a selectively mutated, GC-derived subset within the circulating ASC pool (see Tipton2015 - ASC Diversity and Origin in SLE).

Contradictions & Debates

  • CD138 is not uniformly included in peripheral blood flow cytometry panels for plasmablast identification. Many studies use CD27^hi CD38^hi without CD138, which conflates CD138⁻ and CD138⁺ subsets. Tipton2015 shows these subsets have quantitatively different clonality profiles; studies lacking CD138 sub-gating cannot resolve this distinction.

  • In bone marrow, CD138 marks long-lived plasma cells (Ki67⁻); in peripheral blood, CD138⁺ cells are still Ki67⁺ and circulating. The CD138⁺ fraction in blood should not be equated with bone marrow long-lived plasma cells despite sharing the marker.

  • CD138⁺ ASC enrichment in severe COVID-19: ICU-C patients had significantly higher CD138⁺ ASC frequency both as a fraction of CD19⁺ B cells and as a fraction of total ASCs relative to OUT-C and HD (P ≤ 0.01). In a representative ICU patient, CD138⁺ cells constituted 53% of total ASCs vs. 5.9% in HD. This CD138⁺ enrichment mirrors the pattern in SLE and suggests that severe COVID-19 drives more advanced ASC maturation — or that prolonged EF activation sustains ASC differentiation to the CD138⁺ stage (see Woodruff2020 - EF B Cell Responses in COVID-19, spectral FCM, n=10 ICU-C).

  • ASC populations defined cluster 3 on UMAP: CD138 expression cleanly split the ASC region in UMAP projections into CD138⁻ and CD138⁺ subspaces. This confirms that CD138 is an effective spectral panel marker for resolving ASC maturation stages even in a 24-marker high-dimensional context (see Woodruff2020 - EF B Cell Responses in COVID-19, Fig. 2c–e).

  • Unexpected CD138 expression on CD21lo transitional B cells: In OUT-C patients, CD21lo transitional cells expressed higher CD138 levels than their HD counterparts — a finding noted as atypical, since CD138 expression is typically considered restricted to ASCs. Whether this reflects early plasmablast mis-classification or genuine transitional cell activation remains unclear (see Woodruff2020 - EF B Cell Responses in COVID-19).

  • CD138 included in dengue PB sorting panel: Appanna2016 included CD138 alongside CD20, CD27, CD19, and CD38 in a 5-antibody panel for FACS sorting. Though the primary PB gate was CD19⁺CD20⁻CD27^hiCD38^hi, CD138 presence allowed for maturation-stage resolution within the PB compartment. This is the first dengue study in the wiki to include CD138 in the sorting panel (see Appanna2016 - Plasmablasts as Subset of Memory B Cell Pool, FACSAria, n=12 dengue).

Plasmablast, CD38, CD27, IgD, CD19, Activated Naive B Cell, Extrafollicular Response

Sources

Graph View

Backlinks